Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Teleflex Incorporated (TFX)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
287.30-1.39 (-0.48%)
At close: 04:05PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close288.69
Open290.95
Bid115.22 x 800
Ask399.00 x 1000
Day's Range281.30 - 292.66
52 Week Range256.77 - 428.36
Volume382,113
Avg. Volume369,032
Market Cap13.459B
Beta (5Y Monthly)1.05
PE Ratio (TTM)31.42
EPS (TTM)9.14
Earnings DateApr 27, 2022 - May 02, 2022
Forward Dividend & Yield1.36 (0.49%)
Ex-Dividend DateMay 13, 2022
1y Target Est359.10
  • Benzinga

    RBC Capital Sees Meaningful M&A Execution For This Critical Care-Focused Stock

    Teleflex Inc (NYSE: TFX) hosted its Investor Day and issued plans for 2023-2025. RBC Capital Markets believe TFX is a stronger company delivering stable revenue growth in the M-HSDs, margin expansion, double-digit EPS growth, and strong FCF. It positions Teleflex to execute its capital allocation strategy more meaningfully in the future. TFX has low leverage and enough firepower to execute on ~$2 billion in M&A. The analysts expect a disciplined approach to accretive M&A that will accrue to the

  • GlobeNewswire

    Teleflex Hosts 2022 Analyst & Investor Day

    WAYNE, Pa., May 20, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices, will provide an update on its business and address its 2023-2025 business growth strategy and financial goals during its 2022 Analyst & Investor Day today in New York City. A live webcast of the event presentations will begin at 10:00 a.m. ET and the accompanying presentation materials will be available at that time on the Company’s web site at teleflex.com. “Teleflex is

  • GlobeNewswire

    Teleflex Announces Regulatory Clearance for its UroLift® System in China for the Treatment of Benign Prostatic Hyperplasia (BPH)

    Will expand patient access to BPH treatmentWAYNE, Pa., May 19, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that it has received National Medical Products Administration (NMPA) approval for its UroLift® System in China for treating benign prostatic hyperplasia (BPH). Treatment with the UroLift® System is a minimally invasive approach to treating BPH, commonly known as an enlarged prostate, a condition which may cau

Advertisement
Advertisement